10620 studies found for:    NCI
Show Display Options
Rank Status Study
1 Completed Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: vorinostat;   Drug: paclitaxel;   Drug: carboplatin;   Other: laboratory biomarker analysis;   Other: pharmacological study
2 Completed Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: perifosine
3 Completed Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia
Conditions: Childhood Acute Lymphoblastic Leukemia in Remission;   Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions: Biological: filgrastim;   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide;   Drug: ifosfamide;   Drug: imatinib mesylate;   Drug: leucovorin calcium;   Drug: mercaptopurine tablet;   Drug: methotrexate;   Drug: pegaspargase;   Drug: vincristine sulfate;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: radiation therapy
4 Recruiting Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Conditions: Recurrent Adult Diffuse Large Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
Interventions: Drug: Carboplatin;   Drug: Etoposide;   Drug: Ibrutinib;   Drug: Ifosfamide;   Other: Pharmacological Study;   Biological: Rituximab
5 Active, not recruiting
Has Results
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Conditions: High-grade Salivary Gland Mucoepidermoid Carcinoma;   Low-grade Salivary Gland Mucoepidermoid Carcinoma;   Recurrent Salivary Gland Cancer;   Salivary Gland Acinic Cell Tumor;   Salivary Gland Adenocarcinoma;   Salivary Gland Adenoid Cystic Carcinoma;   Salivary Gland Anaplastic Carcinoma;   Salivary Gland Malignant Mixed Cell Type Tumor;   Salivary Gland Poorly Differentiated Carcinoma;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Salivary Gland Cancer
Interventions: Drug: dasatinib;   Other: laboratory biomarker analysis
6 Completed
Has Results
Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma
Conditions: Contiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Mantle Cell Lymphoma
Interventions: Drug: bortezomib;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine;   Drug: dexamethasone;   Biological: filgrastim;   Biological: pegfilgrastim;   Procedure: Autologous stem cell transplantation (ASCT)
7 Recruiting Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Conditions: Light Chain Deposition Disease;   Smoldering Plasma Cell Myeloma
Interventions: Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment
8 Completed Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
Conditions: Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Hepatosplenic T-cell Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
Intervention: Drug: sorafenib tosylate
9 Active, not recruiting Dinaciclib in Treating Patients With Stage IV Melanoma
Conditions: Acral Lentiginous Malignant Melanoma;   Lentigo Maligna Malignant Melanoma;   Mucosal Melanoma;   Nodular Malignant Melanoma;   Recurrent Melanoma;   Stage IV Melanoma;   Superficial Spreading Malignant Melanoma
Intervention: Drug: dinaciclib
10 Completed Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Drug: topotecan hydrochloride;   Radiation: radiation therapy
11 Completed 506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Conditions: Leukemia;   Lymphoma
Intervention: Drug: nelarabine
12 Completed
Has Results
Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Drug: sunitinib malate;   Other: laboratory biomarker analysis
13 Active, not recruiting Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
Conditions: Colon Mucinous Adenocarcinoma;   Colon Signet Ring Cell Adenocarcinoma;   Lynch Syndrome;   Stage IIA Colon Cancer;   Stage IIB Colon Cancer;   Stage IIC Colon Cancer
Interventions: Biological: Bevacizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin
14 Recruiting Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Conditions: Ductal Breast Carcinoma In Situ;   Estrogen Receptor and/or Progesterone Receptor Positive;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Multicentric Breast Carcinoma;   Multifocal Breast Carcinoma;   Synchronous Bilateral Breast Carcinoma
Interventions: Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate
15 Completed Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
Conditions: Adenocarcinoma of the Colon;   Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage III Colon Cancer;   Stage III Rectal Cancer;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Biological: bevacizumab;   Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: fluorouracil
16 Completed Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Drug: erlotinib hydrochloride
17 Completed Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas
Conditions: Neurofibromatosis Type 1;   Precancerous Condition
Intervention: Drug: pirfenidone
18 Recruiting Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
Conditions: Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Biological: Bevacizumab;   Drug: Irinotecan Hydrochloride;   Drug: Temozolomide
19 Completed Saracatinib in Treating Patients With Recurrent, Stage IIIB or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy That Included Cisplatin or Carboplatin
Conditions: Recurrent Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: saracatinib;   Other: laboratory biomarker analysis
20 Terminated Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy
Conditions: Bladder Adenocarcinoma;   Bladder Squamous Cell Carcinoma;   Bladder Urothelial Carcinoma;   Recurrent Bladder Carcinoma;   Stage I Bladder Cancer;   Stage II Bladder Cancer;   Stage III Bladder Cancer;   Stage IV Bladder Cancer
Interventions: Biological: Recombinant Fowlpox-TRICOM Vaccine;   Biological: Recombinant Fowlpox GM-CSF Vaccine Adjuvant;   Procedure: Therapeutic Conventional Surgery;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years